杭州泰格医药科技股份有限公司 章程修订对照表 | 序号 | 原条款 | 修订后条款 | | --- | --- | --- | | | 第一条 为维护杭州泰格医药科技股份有限 《中华人民共和国证券法》（以下简称《证券 | 简称《公司法》）、《中华人民共和国证券 | | | | 第一条 为维护杭州泰格医药科技股份有 限公司（以下简称"公司"）、股东、职工 | | | 公司（以下简称"公司"）、股东和债权人的 | 和债权人的合法权益，规范公司的组织和行 | | | 合法权益，规范公司的组织和行为，根据《中 | 为，根据《中华人民共和国公司法》（以下 | | | 华人民共和国公司法》（以下简称《公司法》）、 | | | 1 | 法》）、《境内企业境外发行证券和上市管理 | 法》（以下简称《证券法》）、《境内企业 | | | 试行办法》（以下简称《境外上市管理办法》）、 | 境外发行证券和上市管理试行办法》（以下 | | | 《香港联合交易所有限公司证券上市规则》 | 简称《境外上市管理办法》）、《香港联合 | | | （以下简称《香港上市规则》）、《上市公司 | 交易所有限公司证券上市规则》（以下简称 | | | ...

证券代码：300347 证券简称：泰格医药 公告编码（2025）038 号 杭州泰格医药科技股份有限公司 2025 年第一次临时股东会决议的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者重 大遗漏负连带责任。 一、会议召开情况 1、会议召开时间 现场会议召开时间为：2025年9月29日（星期一）下午15：00 网络投票时间：2025年9月29日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为2025年9月29日上午9： 15—9：25，9：30—11：30和下午13：00—15：00；通过深圳证券交易所互联网投票系统 进行网络投票的具体时间为2025年9月29日上午9：15至2025年9月29日下午15：00的任意时 间。 2、现场会议召开地点：杭州市滨江区聚工路19号盛大科技园A座18楼会议室 3、会议方式：本次股东会采取现场投票和网络投票相结合的方式 4、召集人：杭州泰格医药科技股份有限公司董事会 5、现场会议主持人：公司董事长叶小平先生 6、本次股东会会议的召集、召开与表决程序符合《公司法》、《上市公司股东会规则》、 《深圳证券交易所创业板股票上市规 ...

北京市嘉源律师事务所 关于杭州泰格医药科技股份有限公司 2025 年第一次临时股东会的 法律意见书 嘉 源 律师事务所 JIA YUAN LAW OFFICES 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 关于杭州泰格医药科技股份有限公司 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 致:杭州泰格医药科技股份有限公司 北京市嘉源律师事务所 源在到前景 - Pr A YUAN LAW OFFICES 2025 年第一次临时股东会的 法律意见书 嘉源(2025)-04-725 受杭州泰格医药科技股份有限公司(以下简称"公司")委托,北京市嘉源 律师事务所(以下简称"本所")指派律师出席公司 2025年第一次临时股东会 (以下简称"本次股东会"),并依据《中华人民共和国公司法》(以下简称"《公 司法》"）、《上市公司股东会规则》(以下简称"《股东会规则》")、《杭 州泰格医药科技股份有限公司章程》(以下简称"《公司章程》")及《杭州泰 格医药科技股份有限公司股东会议事规则》(以下简称 ...

一、质押变动的基本情况 证券代码：300347 证券简称：泰格医药 公告编码（2025）040 号 杭州泰格医药科技股份有限公司 关于持股 5%以上股东部分股份回购并解除质押的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者重 大遗漏负连带责任。 杭州泰格医药科技股份有限公司（以下简称"公司"）近日接到公司持股5%以上股东曹 晓春女士通知，获悉曹晓春女士办理其持有的部分股份回购并解除质押业务，具体内容如 下： | 曹晓春 | 51,314,174 | 5.96% | 22,600,000 | 20,000,000 | 38.98% | 2.32% | 20,000,000 | 100% | 18,746,330 | 59.87% | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 叶小平 | 177,239,541 | 20.58% | - | - | - | - | - | - | 132,929,656 | 75% | | 合计 | 228,553,715 | 26.54% ...

2025年9月29日，港股上市公司投资日志如下： | 类别 | 公司 | | --- | --- | | | 长风药业 | | 新股活动 | (招股中) | | | 冠军科技集团 | | | OKURA HOLDINGS | | | 健康160 | | | 恒和集团 | | | 中国生态旅游 | | 业绩公布日 | 诺科达科技 | | | PALADIN | | | 大象未来集团 | | | 宝联控股 | | | 时代集团控股 | | | 华音国际控股 QPL INT'L | | | 泰格医药 | | | 南旋控股 | | | 第一拖拉机股份 | | 股东大会召开日 | 财华社集团 | | | 绿色经济 | | | MOS HOUSE | | | 龙升集团控股 | | | 华亿金控 | | | 新华通讯频媒 | | 停复牌 | | | | （复牌） | | 分红派息 | 安乐工程 | | | （派息日） | | | 固生堂 | | | （派息日） | | | 中华汽车 | | | （除净日） | | | 中国船舶租赁 | | | （除净日） | 第一拖拉机股份 （除净日） 上美股份 （除净日） （除净日） 亿 ...

Summary of Conference Call Records Industry Overview - The conference call primarily discusses the **biotechnology and pharmaceutical contract development and manufacturing organization (CDMO)** industry, focusing on companies like **WuXi AppTec**, **Kailai Ying**, and **Boteng** [1][2]. Key Points and Arguments 1. **Order Growth and Capacity Utilization** - WuXi AppTec and Kailai Ying accelerated overseas MNC orders in Q3, leading to increased capacity utilization. Small molecule oral drug orders began to materialize in Q3, expected to contribute to revenue in Q4 and increase gradually next year [1][2]. 2. **Emerging Business Performance** - Kailai Ying's emerging business is nearly at full capacity, particularly in its Tianjin factory, with recent price increases. Boteng's traditional small molecule business also raised prices by approximately 8-10% due to improved capacity utilization, primarily targeting biotech clients [1][5]. 3. **Biosimilar Exemption Benefits** - The exemption for Phase III biosimilars is a significant positive for the large molecule CDMO sector, expected to accelerate overseas orders in Q4 or the first half of next year, positively impacting media and large molecule CGM [1][6]. 4. **Domestic CRO Demand Surge** - Domestic CRO companies saw a further increase in demand in Q3, particularly in pharmacodynamics and toxicology. In vitro pharmacodynamics orders showed a year-on-year growth of 20-30% in H1, reaching 35-40% in Q3, with expectations for continued growth into H1 2026 [1][7][8]. 5. **Biotech Industry Budget Management** - The biotech industry's budget management in 2025 is more relaxed compared to 2024, with reduced pressure on order discounts and price negotiations, leading to an anticipated increase in biotech order prices [1][9]. 6. **Price Trends for Experimental Monkeys** - The price of experimental monkeys increased significantly in Q3, averaging around 95,000 yuan in H1, rising to 110,000-120,000 yuan by late August, reflecting increased demand [1][10]. 7. **Clinical Sector Performance** - The clinical sector saw a 5% growth in total volume in Q3 compared to Q2. Although prices have not yet increased, there is potential for industry-wide price hikes in Q4 due to rising demand and relaxed budgets [1][11]. 8. **Competitive Strategies in Clinical Sector** - Major companies in the clinical sector are adjusting their competitive strategies. For instance, companies like Kailai Ying and KunTuo are focusing on high-margin orders and reducing participation in price wars, which may support future price increases [1][12]. 9. **Impact of External Factors** - The influence of external factors, such as Trump's tweets, on CDMO businesses like WuXi AppTec is limited, as these companies have already engaged with U.S. counterparts regarding capacity issues [1][13][14]. Additional Important Insights - The overall sentiment in the industry is optimistic, with expectations for continued growth in orders and potential price increases across various segments, driven by improved demand and strategic adjustments by key players [1][2][9].

Company Overview - Tigermed (stock code: 300347.SZ/3347.HK) is an integrated biopharmaceutical research and development service platform providing one-stop innovative R&D services and solutions for the global pharmaceutical and medical device industries [2] - Over the past 20 years, the company has collaborated with more than 3,600 partners, creating an innovative ecosystem that empowers the entire industry chain [2] - Tigermed has established over 180 offices and branches globally, employing more than 10,000 professionals across dozens of countries on five continents [2] - The company holds the highest MSCI ESG rating of AAA, a score of 60 on the S&P CSA ESG questionnaire, a B rating (management level) on the CDP climate change questionnaire, and maintains an AAA rating from the Shenzhen Stock Exchange National Index ESG [2] Compliance and Governance - Tigermed has built a compliance governance system covering the entire value chain, with a compliance and ESG committee under the board of directors, directly led by the director and general manager [3] - The company has established a systematic compliance risk management process, with specialized compliance groups regularly identifying, assessing, and responding to operational risks [3] - A multi-level supervision and risk identification mechanism is in place, covering headquarters, subsidiaries, and business departments, to ensure compliance and operational stability [3] Anti-Corruption and Data Security - The company has implemented a comprehensive anti-corruption and anti-bribery policy, with plans for company-wide anti-corruption training in 2024 [4] - Suppliers are required to sign a "Supplier Code of Conduct" and "Anti-Bribery and Anti-Corruption Commitment" during the onboarding process to ensure awareness of the company's policies [4] - Tigermed is continuously optimizing its data security management system, with measures to enhance network security, data lifecycle management, and information access control [4] - The company holds an ISO 27001:2013 information security management system certification, and three core business systems have passed the national information security level protection tier three certification [4] Intellectual Property Management - Tigermed views intellectual property as a crucial competitive advantage, having established various management policies and training programs related to intellectual property compliance [5] - The company is actively planning its intellectual property strategy and aims to achieve GB/T 29490-2023 intellectual property compliance management system certification in 2024 [5] Expert Commentary - In 2024, Tigermed will embed compliance objectives into executive assessments, with anti-corruption training covering all employees and 80% of global business (excluding listed subsidiaries) completing anti-corruption audits [5] - The requirement for suppliers to sign the "Anti-Bribery Commitment" ensures adherence to legal and ethical standards [5]

Group 1 - The top three companies with the highest short positions as of September 19 are ZTE Corporation (00763) at 15.35%, COSCO Shipping Holdings (01919) at 14.10%, and CATL (03750) at 13.44% [1][2] - The companies with the largest absolute increase in short positions are China Education Holdings (00839) with an increase of 2.61%, Dongfang Electric (01072) with an increase of 2.06%, and Xiexin Technology (03800) also with an increase of 2.06% [1][2] - The companies with the largest absolute decrease in short positions are Hua Hong Semiconductor (01347) with a decrease of -2.52%, Chifeng Jilong Gold Mining (06693) with a decrease of -1.77%, and Laikai Pharmaceutical-B (02105) with a decrease of -1.72% [1][2] Group 2 - The latest short position data shows that ZTE Corporation maintained 116 million shares, COSCO Shipping Holdings had 406 million shares, and CATL had 20.95 million shares [2] - The companies with the largest increase in short positions include China Education Holdings, which rose from 3.73% to 6.33%, and Dongfang Electric, which rose from 7.34% to 9.40% [2] - The companies with the largest decrease in short positions include Hua Hong Semiconductor, which fell from 9.00% to 6.48%, and Chifeng Jilong Gold Mining, which fell from 3.30% to 1.53% [2][3]

Market Overview - The Hong Kong stock market experienced significant declines, with the Hang Seng Index falling by 1.35% to close at 26,128.2 points, and a total trading volume of HKD 3,236.74 million [1] - The Hang Seng Tech Index dropped by 2.89%, while the Hang Seng China Enterprises Index decreased by 1.49% [1] - Weekly performance showed cumulative declines of 1.57% for the Hang Seng Index, 1.79% for the China Enterprises Index, and 1.58% for the Tech Index [1] Blue-Chip Stocks Performance - Xiaomi Group-W (01810) led the blue-chip decline, falling 8.07% to HKD 54.65, impacting the Hang Seng Index by 137.07 points [2] - Other notable blue-chip movements included Hang Seng Bank (00011) rising 3.23% and Mengniu Dairy (02319) increasing by 2.87% [2] - Semiconductor stocks showed mixed results, with SMIC (00981) down 5.01% and Hua Hong Semiconductor (01347) up 3.02% [2][11] Sector Performance - Large tech stocks generally declined, with Xiaomi's new product launch contributing to its drop [3] - Pharmaceutical stocks faced pressure due to new tariffs announced by President Trump, with many stocks in this sector declining significantly [4][3] - Wind energy stocks performed well, with companies like Goldwind Technology (002202) rising over 4% [4][5] Wind and Nuclear Energy Insights - Morgan Stanley reported a positive outlook for the Chinese wind energy sector, predicting a turnaround in pricing and profitability by early 2025 [5] - The report anticipates an average annual new installed capacity exceeding 110 GW during the "14th Five-Year Plan" period [5] - Nuclear energy stocks also saw gains, with China National Nuclear Power (02302) increasing by 8.91% [6] Notable Stock Movements - Xinjiang Xinxin Mining (03833) surged 32.43% after announcing plans to issue A-shares [7] - Jiali International (01050) rose 33.33% after being included in NVIDIA's supplier list [8] - Xiaopeng Motors-W (09868) gained 5.03% as it announced market entry into several European countries [10]

Market Overview - The Hong Kong stock market experienced significant declines, with the Hang Seng Index dropping 1.35% to close at 26,128.2 points, and the Hang Seng Technology Index falling 2.89% to 6,195.11 points. The total trading volume for the day was 323.67 billion HKD [1] - Weekly performance showed the Hang Seng Index down 1.57%, the Hang Seng China Enterprises Index down 1.79%, and the Hang Seng Technology Index down 1.58% [1] Blue-Chip Stocks Performance - Xiaomi Group-W (01810) led the decline among blue-chip stocks, falling 8.07% to 54.65 HKD, contributing a loss of 137.07 points to the Hang Seng Index. The company launched its new Xiaomi 17 series smartphones, with prices starting at 4,499 HKD [2] - Other notable blue-chip movements included Hang Seng Bank (00011) rising 3.23% to 118.2 HKD, and Mengniu Dairy (02319) increasing by 2.87% to 14.71 HKD. Conversely, Semiconductor Manufacturing International Corporation (00981) fell 5.01% to 72.95 HKD [2] Sector Performance - Large technology stocks generally declined, with Xiaomi dropping over 8%, Alibaba down over 3%, and Tencent nearly 1% [3] - Pharmaceutical stocks faced pressure due to new tariffs announced by President Trump, which will impose a 100% tariff on branded and patented drugs starting October 1. However, the impact on Hong Kong's innovative drug sector is expected to be limited [4][3] - Wind power stocks saw gains, with China High-Speed Transmission (00658) up 5.45% and Goldwind Technology (02208) up 4.13% [4] Wind Power Industry Insights - Morgan Stanley reported that after a three-year downturn, the Chinese wind power value chain has successfully reversed negative competition through industry self-discipline. The firm expects domestic wind power installation demand to remain resilient, with annual new installations projected to exceed 110 GW during the 14th Five-Year Plan period [5] Nuclear Power Sector - Nuclear power stocks rose, with China National Nuclear Power (02302) increasing by 8.91% and China General Nuclear Power (01164) up 5.23% [5] - The market is experiencing a surge in demand for nuclear energy and AI, while major producers are cutting output, leading to a supply bottleneck. Uranium prices have risen approximately 5% this year due to these dynamics [5] Notable Stock Movements - Xinjiang Xin Mining (03833) surged 32.43% to 2.45 HKD after announcing plans to issue A-shares and list on a Chinese stock exchange [6] - Jiali International (01050) rose 33.33% to 2.48 HKD after being included in NVIDIA's qualified supplier list [7] - Boleton (01333) increased by 20.2% to 46.18 HKD following a strategic cooperation agreement in the autonomous mining transport sector [8] - XPeng Motors-W (09868) gained 5.03% to 90.8 HKD as it announced its entry into five European markets [9] - Hua Hong Semiconductor (01347) reached a new high, closing up 3.02% at 68.25 HKD, with expectations of improved pricing negotiations in 2025 [10]